Full Press Release Details
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production.
IRON
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Key Takeaway: Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+45%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Cash runway
~48 mo
Minimal dilution risk
Lead asset
DISC-0974
Phase 2 · Inflammatory Bowel Disease (IBD)